医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meiji Seika Pharma Co., Ltd: Support for Control of Novel Coronavirus in China

2020年02月21日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan: “Meiji”) announced today that Meiji decided a financial donation to support coronavirus outbreak control in China.

Daikichiro Kobayashi, President and Representative Director said “First of all, we extend our sincerest condolences to the victims and their families. For about 30 years, we have been operating its business in Guangdong and Shandong, and we greatly appreciate the customers and partners all over in China. We would like to give our support to everyone there and hope our donation helps.”

We sincerely pray for early recovery of Novel coronavirus associated pneumonia patients and the end of virus infection in China.

Details of the donation
- Amount of contribution: RMB 1 million (approximately JPY 16 million)
- Donated to: Red Cross Society of China

View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005336/en/

CONTACT

Beijing Office: (010)65388196

Zhao Chengguo

https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 武田通过与Moderna和日本政府合作,在日本扩大COVID-19疫苗供货
  • ABEC将向百因诺生物交付业内首台6000L一次性生物反应器
  • Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia
  • The McQuade Center for Strategic Research and Development Enters Collaboration Agreement with Rugen Holdings (Cayman) Limited to Develop Novel Treatment for Patients with Diverse Psychiatric Disorders
  • 国連世界都市デーを機に、G20のアーバン20(U20)エンゲージメント・グループがCOVID-19を受けて「世界都市強靭性基金」の創設を発表